One can think of the life of a bioassay in two main acts. First comes the design and development of the assay, where the assay method is conceptualised, refined,... read more →
One common use for bioassays is to test manufactured biologic products before they are released to the wider consumer market. While all bioassays used for this purpose will have... read more →
It is far from a controversial statement that biologic therapeutics – such as monoclonal antibody and recombinant protein therapies – are complex and expensive to develop. As one might... read more →
Statistics is hard, words are harder. So often when working through the statistics behind a bioassay, the correct path is obscured behind a word salad of jargon placed seemingly... read more →
So far in our series examining approaches to outlier management in bioassay, we’ve discussed the various perspectives on outliers held by stakeholders in the bioassay lifecycle and the problems... read more →